Zevra Therapeutics

(NASDAQ) ZVRA

Current Price$12.77

Market Cap$772.04M

Since IPO (2015)-93%

5 Year+16%

1 Year+2%

1 Month+3%

Zevra Therapeutics Financials at a Glance

Market Cap

$772.04M

Revenue (TTM)

$122.29M

Net Income (TTM)

$124.22M

EPS (TTM)

$2.15

P/E Ratio

6.06

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Price

$12.77

Volume

7,003

Open

$13.03

Price

$12.77

Volume

7,003

Open

$13.03

Previous Close

$13.06

Daily Range

$12.75 - $13.05

52-Week Range

$7.16 - $15.04

Estimated Earnings Date

Aug 11, 2026

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Price

$12.77

Volume

7,003

Open

$13.03

Previous Close

$13.06

Daily Range

$12.75 - $13.05

52-Week Range

$7.16 - $15.04

Estimated Earnings Date

Aug 11, 2026

ZVRA News

Person checking medicine on a shelf in a pharmacy

ZVRA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zevra Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Neil F. McFarlane

Website

zevra.com

Headquarters

Celebration, FL 34747, US

ZVRA Financials

Key Financial Metrics (TTM)

Gross Margin

85.51%

Operating Margin

-39.86%

Net Income Margin

101.58%

Return on Equity

81.34%

Return on Capital

-1.94%

Return on Assets

44.59%

Earnings Yield

16.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$772.04M

Shares Outstanding

59.12M

Volume

7.00K

Avg. Volume

1.67M

Financials (TTM)

Gross Profit

$104.57M

Operating Income

-$48.75M

EBITDA

$140.47M

Operating Cash Flow

$12.77M

Capital Expenditure

-$771.00K

Free Cash Flow

$12.00M

Cash & ST Invst.

$95.60M

Total Debt

$1.15M

Zevra Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$36.22M

+77.5%

Gross Profit

$33.96M

+78.2%

Gross Margin

93.75%

N/A

Market Cap

$772.04M

N/A

Market Cap/Employee

$12.66M

N/A

Employees

N/A

Net Income

$37.89M

+1322.7%

EBITDA

$43.46M

+2455.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$95.60M

+52.6%

Total Debt

$1.15M

-98.1%

Accounts Receivable

$22.10M

+75.1%

Inventory

$2.31M

-9.7%

Long Term Debt

$741.00K

-98.8%

Short Term Debt

$406.00K

-31.1%

Return on Assets

44.59%

N/A

Return on Invested Capital

-21.05%

N/A

Free Cash Flow

$6.11M

+173.4%

Operating Cash Flow

$6.14M

+174.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

RIGLRigel Pharmaceuticals, Inc.

RIGLRigel Pharmaceuticals, Inc.$41.13-0.10%

RGNXREGENXBIO Inc.

RGNXREGENXBIO Inc.$11.92-3.01%

VTYXVentyx Biosciences, Inc.

VTYXVentyx Biosciences, Inc.$14.00+0.00%

OLMAOlema Pharmaceuticals, Inc.

OLMAOlema Pharmaceuticals, Inc.$11.81-0.35%

PRTAProthena Corporation plc

PRTAProthena Corporation plc$8.49-1.73%

AKBAAkebia Therapeutics, Inc.

AKBAAkebia Therapeutics, Inc.$1.37-2.14%

CRVSCorvus Pharmaceuticals, Inc.

CRVSCorvus Pharmaceuticals, Inc.$14.91-0.40%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$15.74+0.00%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$72.69-0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$12.14-0.02%

ERNAErnexa Therapeutics

ERNAErnexa Therapeutics$6.67+0.10%

TAT&T

TAT&T$21.44+0.01%

BMNRBitmine Immersion Technologies

BMNRBitmine Immersion Technologies$15.87-0.03%

MARAMara Holdings

MARAMara Holdings$11.73-0.04%

Questions About ZVRA

What is the current price of Zevra Therapeutics?

Zevra Therapeutics is trading at $12.77 per share.

What is the 52-week range for Zevra Therapeutics?

Over the past 52 weeks, Zevra Therapeutics has traded between $7.16 and $15.04.

How much debt does Zevra Therapeutics have?

As of the most recent reporting period, Zevra Therapeutics reported total debt of $1.15M.

How much cash does Zevra Therapeutics have on hand?

Zevra Therapeutics reported $95.60M in cash and cash equivalents in its most recent financial results.

What is Zevra Therapeutics’s dividend yield?

Zevra Therapeutics does not currently have a dividend yield.

Zevra Therapeutics

Zevra Therapeutics Financials at a Glance

ZVRA News

Why Zevra Therapeutics Stock Zoomed 21% Higher Today

Zevra Revenue Jumps 486 Percent in Q2

Why KemPharm Stock Sank Today

ZVRA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Zevra Therapeutics

ZVRA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Zevra Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ZVRA

What is the current price of Zevra Therapeutics?

What is the 52-week range for Zevra Therapeutics?

How much debt does Zevra Therapeutics have?

How much cash does Zevra Therapeutics have on hand?

What is Zevra Therapeutics’s dividend yield?

Premium Investing Services